Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma.

Szczegóły
Abstrakt

Tytuł:: Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma.
Autorzy:: Breyer J; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. .
Gierth M; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany.
Shalekenov S; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany.
Aziz A; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany.; Department of Urology, University of Hamburg, Hamburg, Germany.
Schäfer J; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany.
Burger M; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany.
Denzinger S; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany.
Hofstädter F; Institute of Pathology, University of Regensburg, Regensburg, Germany.
Giedl C; Institute of Pathology, University of Regensburg, Regensburg, Germany.
Otto W; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany.
Źródło:: World journal of urology [World J Urol] 2016 May; Vol. 34 (5), pp. 709-16. Date of Electronic Publication: 2015 Sep 22.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: [Berlin ; New York] : Springer International, 1983-
MeSH Terms:: Epithelial-Mesenchymal Transition*
Cadherins/*analysis
Carcinoma, Transitional Cell/*chemistry
Carcinoma, Transitional Cell/*pathology
Inhibitor of Apoptosis Proteins/*analysis
Urinary Bladder Neoplasms/*chemistry
Urinary Bladder Neoplasms/*pathology
Aged ; Aged, 80 and over ; Antigens, CD ; Disease Progression ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Retrospective Studies ; Survivin
References:: Nat Rev Cancer. 2007 Jun;7(6):415-28. (PMID: 17508028)
Pathol Oncol Res. 2006;12(1):13-9. (PMID: 16554911)
Mod Pathol. 2006 Nov;19(11):1487-97. (PMID: 16892011)
Eur J Cancer. 2000 Feb;36(3):357-62. (PMID: 10708937)
J Clin Invest. 2009 Jun;119(6):1420-8. (PMID: 19487818)
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4407-14. (PMID: 17671123)
Clin Cancer Res. 2009 Nov 15;15(22):7012-9. (PMID: 19903782)
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. (PMID: 20610543)
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108. (PMID: 15761078)
Clin Exp Metastasis. 2008;25(6):629-42. (PMID: 18461285)
Eur Urol. 2013 Oct;64(4):639-53. (PMID: 23827737)
J Urol. 2001 May;165(5):1473-9. (PMID: 11342899)
Mol Cancer Res. 2012 Aug;10(8):995-1009. (PMID: 22714124)
Cancer Res. 1994 Jun 15;54(12 ):3120-3. (PMID: 8205527)
Urol Oncol. 2009 May-Jun;27(3):268-76. (PMID: 18440840)
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. (PMID: 16442208)
Genet Mol Res. 2013 Apr 02;12(2):1045-53. (PMID: 23613251)
J Cancer Res Clin Oncol. 1995;121(5):303-8. (PMID: 7768969)
Urol J. 2012 Summer;9(3):581-5. (PMID: 22903481)
Am J Clin Pathol. 2006 Jan;125(1):119-26. (PMID: 16483000)
Hum Pathol. 2002 Oct;33(10):996-1000. (PMID: 12395372)
Am J Pathol. 2012 Jun;180(6):2188-200. (PMID: 22542493)
N Engl J Med. 1999 Aug 5;341(6):452-3. (PMID: 10438269)
Virchows Arch. 2006 Mar;448(3):277-87. (PMID: 16328348)
Urology. 2007 Sep;70(3):482-6. (PMID: 17905101)
Korean J Urol. 2013 Oct;54(10):645-50. (PMID: 24175036)
J Pathol. 2008 Jun;215(2):184-94. (PMID: 18393367)
J Urol. 2010 Aug;184(2):423-31. (PMID: 20620393)
PLoS One. 2013 Oct 18;8(10):e76719. (PMID: 24204662)
Contributed Indexing:: Keywords: E-cadherin; EMT; Immunohistochemistry; Non-muscle-invasive bladder cancer; Stage pTa bladder cancer; Survivin
Substance Nomenclature:: 0 (Antigens, CD)
0 (BIRC5 protein, human)
0 (CDH1 protein, human)
0 (Cadherins)
0 (Inhibitor of Apoptosis Proteins)
0 (Survivin)
Entry Date(s):: Date Created: 20150924 Date Completed: 20170418 Latest Revision: 20220331
Update Code:: 20221216
DOI:: 10.1007/s00345-015-1690-5
PMID:: 26394624
: Czasopismo naukowe

Full Text Finder

Purpose: To determine whether the immunohistochemical markers survivin and E-cadherin can predict progress at initially diagnosed Ta bladder cancer.
Methods: We retrospectively searched for every initially diagnosed pTa urothelial bladder carcinoma having been treated at our single-center hospital in Germany from January 1992 up to December 2004. Follow-up was recorded up to June 2010, with recurrence or progress being the endpoints. Immunohistochemical staining and analysis of survivin and E-cadherin of the TURB specimens were performed. Outcome dependency of progression and no progression with immunohistochemical staining was analyzed using uni- and multivariate regression analysis, Kaplan-Meier analysis and uni- and multivariate Cox regression analysis.
Results: Overall, 233 patients were included. Forty-two percent of those were tumor free in their follow-up TURBs, 46 % had at least one pTa recurrence and 12 % even showed progress to at least pT1 bladder cancer. Aberrant staining of E-cadherin was found within 71 % of patients with progression in contrast to only 40 % in cases without progression (p = 0.004). Of all progressed patients, 92 % showed overexpression of survivin in their initial pTa specimen compared to 61 % without progression (p = 0.001). Kaplan-Meier analysis revealed aberrant E-cadherin staining to be associated with worse progression-free survival (PFS) (p = 0.005) as well as overexpression of survivin (p = 0.003). In multivariate Cox regression analysis, strong E-cadherin staining was an independent prognosticator for better PFS (p = 0.033) and multifocality (p = 0.046) and tumor size over 3 cm (p = 0.042) were prognosticators for worse PFS.
Conclusion: Adding the immunohistochemical markers survivin and E-cadherin could help to identify patients at risk of developing a progressive disease in initial stage pTa bladder cancer.

Informacja